Rna Diagnostics' News - Clinical findings presented with good reception in Cremona, Italy, opportunities for RDA in UK and Germany, Dr. Sanaa Noubir joins RnaDx as Clinical Development Manager.


Fall 2013

Clinical trial outcomes presented in Cremona, Italy 

Rna Diagnostics (RnaDx) presented the findings of three clinical trials at the 5th International Symposium, Primary Systemic Treatment in the Management of Operable Breast Cancer in Cremona Italy. Dr. Ken Pritzker’s presentation, "RNA disruption as a measure of drug response in neoadjuvant therapy", was well received by the select audience of international experts. This conference drew together leaders in the field of primary breast cancer treatment with a particular focus on neoadjuvant therapy.

The audience reception was very encouraging. “People are looking for a reliable response marker,” Dr. Pritzker, CEO of Rna Diagnostics states. “RDA™ appears to be the leading assessment marker they are looking for.”

Part of the clinical work presented was performed in collaboration with the Azienda Istituti Ospitalieri di Cremona,  Cremona, Italy. It showed that the RDA test can detect RNA disruption as early as 15 days from the start of chemotherapy. It also demonstrated that RDA was effective in three different classes of drugs. The paper will be published soon by Oxford University Press in the Journal of the National Cancer Institute (JNCI).

Opportunities for RDA™ in the UK and Germany

John Connolly, Rna Diagnostics’ VP Corporate Development, has initiated programs in the UK and Germany that will lead to engagement with the national healthcare systems of these key markets.  John met with the National Institute for Health and Clinical Excellence (NICE) in Manchester, England.  NICE advises the UK National Health Service on the adoption of new health technologies. NICE encouraged Rna Diagnostics to pursue its Medical Technologies Evaluation Programme, a programme that will lead to national adoption and reimbursement in the United Kingdom.

In Germany we have engaged in a programme to introduce RDA to the “Gemeinsamer Bundesausschuss”  (G-BA), the body charged with clinical adoption and reimbursement and a programme to prepare for “selective contracting”,  a requirement for initiating targeted sales in Germany. 

Dr. Sanaa Noubir, Clinical Development Manager

We are pleased to announce that Dr. Sanaa Noubir has been hired as Clinical Development Manager for Rna Diagnostics. Dr. Noubir will assist in the development and management of collaborations with clinical partners and develop integrated programs to stimulate market awareness and early adopters for RDA.

“We’re delighted to have Dr. Noubir  join us as she brings a wealth of experience and knowledge in cell biology plus recent training in business administration,” say Dr. Ken Pritzker, CEO of Rna Diagnostics.  “We look forward to having her help advance RDA towards market by increasing our liaison with key opinion leaders and other interested parties.”

Dr. Noubir has a PhD in Genetics and Molecular Biology from the University of Paris Sud XI, Orsay, France. She has an MBA from the Schulich School of Business, York University.

Dr. Sanaa Noubir joins Rna Diagnostics as Clinical Development Manager.

RnaDx receives MEDEC funding

RnaDx has been awarded a MEDEC-CMMA New Horizons for MedTech (NHM) Program grant of $30,000. Funding will be used to initiate reimbursement and early adopter market entry in Germany where neoadjuvant therapy is a primary method of treating breast cancer.

Getting the word out in Japan 

Dr. Ken Pritzker was part of the Ontario Personalized Medicine Delegation, Science and Technology  Mission to Asia in early October. He participated in several business seminars and presented with a very good positive reception, to oncologists at Ariake Cancer Hospital. 

Upcoming Events

December 10-14 – San Antonio Breast Cancer Symposium, San Antonio, Texas.  Rna Diagnostics’ Chief Scientific Officer  Dr. Amadeo Parissenti will present a poster, “ High tumor RNA disruption is associated with increased survival in patients with locally advanced breast cancer”.

Management Team

Ken Pritzker, MD, FRCPC
President & CEO
Amadeo Parissenti, PhD
Chief Scientific Officer
John Connolly, MBA
VP Corporate Development
John Jordan, MBA, CMA
Chief Financial Officer
Laura Pritzker, PhD
Principal Scientist

Clinical Advisory Board

Maureen E. Trudeau, MA, MD, FRCPC, Toronto, Canada
Gunter von Minckwitz, MD, PhD, Frankfurt, Germany
Michael Untch, MD, PhD, Berlin, Germany
Harry D. Bear, MD, PhD, Richmond, VA, USA

Rna Diagnostics Inc. is a Canadian molecular diagnostics company developing diagnostic tools to improve chemotherapy management.

Our mailing address is:
Rna Diagnostics Inc.
MaRS Centre, Heritage Building, 101 College Street, Suite HL20-4, Toronto, ON, Canada
Toronto, ON M5G 1L7

Add us to your address book
For more information contact:
John Connolly
VP Corporate Development